本帖最后由 老马 于 2013-3-13 13:43 编辑
% a) ^2 c. I5 U/ h" q& j5 C. O3 T: r- Q! k+ j
健择（吉西他滨）+顺铂+阿瓦斯汀# F) y x* E2 m4 P& o
Gemzar +Cisplatin + Avastin
, _& J1 u: j3 m, `) M+ ]/ Shttp://annonc.oxfordjournals.org/content/21/9/1804.full- h9 p5 q N' L1 j2 t: l; Z6 X1 O) t' H
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
2 u2 ?, A& T& hPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. % o7 X- I! W/ i" ^8 R' K
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. 9 z. Y" X, v0 C
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 265)
) r3 |- _: f8 G7 h8 U
华为网盘附件：" v8 I" q2 C. }; ]& f
【华为网盘】ava.JPG- e) _- E% X( L3 I$ Q
|
显身卡
